The Effect of the Average Manufacturer Price Final Rule on Drug Pricing and Contracting, Part 2: Opportunities and Barriers in Pharmaceutical Pricing
Watch the Video on Youtube or Here:
Join Epstein Becker Green and EBG Advisors for a webinar series that examines the average manufacturer price (“AMP”) Final Rule and its effect on drug pricing and contracting.
The long-awaited issuance of the Final Rule addressing AMP under the Medicaid Drug Rebate Program has provided clarity in some respects but left other issues open to interpretation. In the wake of the Final Rule, other regulatory developments are already showing signs of further impacting many of the same issues.
Using the AMP Final Rule as a baseline, we will address the evolution of some of the most significant issues affecting drug pricing and contracting. We hope you can attend one or both of the sessions in this two-part series.
In this session, Dr. Samuel R. Nussbaum, M.D., Strategic Consultant at EBG Advisors, and Lesley R. Yeung, Associate at Epstein Becker Green, will examine the pay-for-value and alternative approaches to pharmaceutical pricing. The speakers will discuss opportunities and barriers as well as highlight real-world examples.
Have a question on any of these issues? Please email the session speaker or Whitney Krebs, Business Development Manager, at [email protected].